Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Choudhury

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Biorxiv : the Preprint Server for Biology|January 9, 2026
Convergent evolution on <i>RBA1</i> regulates <i>Candidozyma auris</i> host adaptationLaura A Doorley, Alyssa A La Bella, Sarah J Jones, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Nutrient excess remodels islet autonomic innervation via pancreatic schwann cellsR F Hampton, M Jimenez-Gonzalez, R Kang, et al.
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J Choudhury, Antonio Marra, Jane S Y Sui, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2025
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung CancerJessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2026
Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentationR Philips, A Mahajan, L Estephan, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Biorxiv : the Preprint Server for Biology|January 9, 2026
Convergent evolution on <i>RBA1</i> regulates <i>Candidozyma auris</i> host adaptationLaura A Doorley, Alyssa A La Bella, Sarah J Jones, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Nutrient excess remodels islet autonomic innervation via pancreatic schwann cellsR F Hampton, M Jimenez-Gonzalez, R Kang, et al.
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J Choudhury, Antonio Marra, Jane S Y Sui, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2025
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung CancerJessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2026
Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentationR Philips, A Mahajan, L Estephan, et al.
Pageof 6